相似文献
1
Physiological and pathological properties of alpha-synuclein.
Cell Mol Life Sci. 2007 Sep;64(17):2194-201. doi: 10.1007/s00018-007-7217-5.
2
Alpha-synuclein dysfunction in Lewy body diseases.
Mov Disord. 2005 Aug;20 Suppl 12:S37-44. doi: 10.1002/mds.20538.
3
Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Mov Disord. 2013 Jan;28(1):31-40. doi: 10.1002/mds.25373.
4
Parkinson's disease and α-synuclein expression.
Mov Disord. 2011 Oct;26(12):2160-8. doi: 10.1002/mds.23948. Epub 2011 Sep 1.
5
Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain.
Brain. 2015 Jun;138(Pt 6):1642-57. doi: 10.1093/brain/awv040. Epub 2015 Mar 1.
6
Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein.
Curr Protein Pept Sci. 2009 Oct;10(5):483-99. doi: 10.2174/138920309789351921.
7
Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations.
J Bioenerg Biomembr. 2010 Feb;42(1):85-95. doi: 10.1007/s10863-009-9258-y. Epub 2010 Feb 11.
8
The good and bad of therapeutic strategies that directly target α-synuclein.
IUBMB Life. 2020 Apr;72(4):590-600. doi: 10.1002/iub.2194. Epub 2019 Nov 6.
9
Α-synuclein misfolding and Parkinson's disease.
Biochim Biophys Acta. 2012 Feb;1822(2):261-85. doi: 10.1016/j.bbadis.2011.10.002. Epub 2011 Oct 12.
10
Pathogenic Impact of α-Synuclein Phosphorylation and Its Kinases in α-Synucleinopathies.
Int J Mol Sci. 2022 Jun 1;23(11):6216. doi: 10.3390/ijms23116216.
引用本文的文献
1
Bacterial products initiation of alpha-synuclein pathology: an in vitro study.
Sci Rep. 2024 Dec 5;14(1):30306. doi: 10.1038/s41598-024-81020-x.
2
Targeting Protein Misfolding and Aggregation as a Therapeutic Perspective in Neurodegenerative Disorders.
Int J Mol Sci. 2024 Nov 20;25(22):12448. doi: 10.3390/ijms252212448.
3
Identification of SYNJ1 in a Complex Case of Juvenile Parkinsonism Using a Multiomics Approach.
Int J Mol Sci. 2024 Sep 9;25(17):9754. doi: 10.3390/ijms25179754.
4
Exploring Intrinsic Disorder in Human Synucleins and Associated Proteins.
Int J Mol Sci. 2024 Aug 1;25(15):8399. doi: 10.3390/ijms25158399.
5
In vitro modulation of mTOR and mGlur5 influence α-synuclein accumulation.
Mol Brain. 2024 Feb 15;17(1):9. doi: 10.1186/s13041-023-01074-2.
6
Calcineurin stimulation by Cnb1p overproduction mitigates protein aggregation and α-synuclein toxicity in a yeast model of synucleinopathy.
Cell Commun Signal. 2023 Aug 24;21(1):220. doi: 10.1186/s12964-023-01242-w.
7
Clinical neurophysiology of Parkinson's disease and parkinsonism.
Clin Neurophysiol Pract. 2022 Jun 30;7:201-227. doi: 10.1016/j.cnp.2022.06.002. eCollection 2022.
8
Gene-Based Therapeutics for Parkinson's Disease.
Biomedicines. 2022 Jul 26;10(8):1790. doi: 10.3390/biomedicines10081790.
9
Brain regions susceptible to alpha-synuclein spreading.
Mol Psychiatry. 2022 Jan;27(1):758-770. doi: 10.1038/s41380-021-01296-7. Epub 2021 Sep 24.
10
Protein Aggregation Landscape in Neurodegenerative Diseases: Clinical Relevance and Future Applications.
Int J Mol Sci. 2021 Jun 2;22(11):6016. doi: 10.3390/ijms22116016.
Zotero 插件